The mutation status of the epidermal growth factor receptor (EGFR) as a selection criterion for therapy with EGFR tyrosine kinase inhibitors (TKI's) in non-small cell lung cancer (NSCLC).

被引:0
|
作者
Mathy, A. [1 ]
Nederlof, P. [1 ]
Boerrigter, L. [1 ]
Van 't Veer, L. [1 ]
De Jong, D. [1 ]
Baas, P. [1 ]
Burgers, S. [1 ]
Van Zandwijk, N. [1 ]
机构
[1] Netherlands Canc Inst, Amsterdam, Netherlands
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
10073
引用
收藏
页码:558S / 558S
页数:1
相关论文
共 50 条
  • [1] Efficacy and safety of epidermal growth factor receptor (EGFR) - Tyrosine kinase inhibitors (TKI) in elderly patients with EGFR mutation-positive non-small cell lung cancer (NSCLC)
    Takeyasu, Y.
    Goto, Y.
    Morita, R.
    Sato, J.
    Murakami, S.
    Horinouchi, H.
    Fujiwara, Y.
    Kanda, S.
    Yamamoto, N.
    Ohe, Y.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [2] Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer
    Cascone, T
    Morelli, MP
    Ciardiello, F
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 46 - 48
  • [3] Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR mutations in Singapore
    Chua, B.
    Tan, E. H.
    Lim, D. W-T.
    Ang, M-K.
    Tan, D. S. W.
    Ng, Q-S.
    Kanesvaran, R.
    Jain, A.
    Tan, W-L.
    Toh, C. K.
    Rajasekaran, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [4] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
    Gelatti, Ana C. Z.
    Drilon, Alexander
    Santini, Fernando C.
    [J]. LUNG CANCER, 2019, 137 : 113 - 122
  • [5] Treatment of brain metastases in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: the role of EGFR tyrosine kinase inhibitors
    Karachaliou, Niki
    Rosell, Rafael
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2013, 2 (03) : 114 - 117
  • [6] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CO-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AND RESPONSE TO EGFR TYROSINE KINASE INHIBITORS (TKIS)
    Barnet, Megan B.
    O'Toole, Sandra
    Horvath, Lisa' G.
    Selinger, Christina
    Yu, Bing
    Trent, Ronald
    Ng, Chiu Chin
    Boyer, Michael J.
    Cooper, Wendy
    Kao, Steven
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 156 - 156
  • [7] Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).
    Keam, Bhumsuk
    Kim, Dong-Wan
    Park, Jin Hyun
    Lee, Jeong-Ok
    Kim, Tae Min
    Lee, Se-Hoon
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Heo, Dae Seog
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)
    Raez, L. E.
    Baca, Y.
    Nagasaka, M.
    Nieva, J.
    Mandani, H.
    Wanderwalde, A.
    Borghaei, H.
    Naban, C.
    Langer, C.
    Socinsky, M. A.
    Lopes, G.
    Khan, H.
    Wozniak, A.
    Carracedo, C.
    Liu, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S597 - S597
  • [9] Epidermal Growth Factor Receptor (EGFR) mutation testing in non-small cell lung cancer (NSCLC) patients
    Eaton, Helen
    Dutton, L.
    Wallace, A. J.
    Howard, E.
    Gaunt, L.
    Blackhall, F.
    Newman, W.
    [J]. JOURNAL OF MEDICAL GENETICS, 2011, 48 : S72 - S72
  • [10] Epidermal Growth Factor Receptor (EGFR) Mutation Testing in non-small cell lung cancer (NSCLC) patients
    Wallace, Andrew
    Howard, E.
    Dutton, L.
    Elles, R. G.
    Newman, W.
    [J]. JOURNAL OF MEDICAL GENETICS, 2010, 47 : S66 - S66